Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy
Clinical trial NCT05206513 · COMPLETED
Trial details
- NCT number
- NCT05206513
- Sponsor
- Neurocrine Biosciences
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-04-15
- Primary completion
- 2025-10-16
- Enrollment
- 86
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.